Relapse Prevention to Reduce HIV Among Women Prisoners
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Opioid Relapse
Intervention: Suboxone (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Overall contact:
Karen Cropsey, Psy.D., Phone: 205-917-3786, Ext: 205, Email: kcrospey@beapsy1.his.uab.edu
Summary
This study is a feasibility and acceptability study assessing whether providing
buprenorphine for women under criminal justice supervision leaving a controlled environment
and returning to the community would prevention opioid relapse.
Clinical Details
Official title: Relapse Prevention to Reduce HIV Among Women Prisoners
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment
Primary outcome: acceptability and feasibilityacceptability and feasibility
Eligibility
Minimum age: 19 Years.
Maximum age: 65 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- female, history of opioid dependence, released back to the community from a
controlled environment, criminal justice involvment
Exclusion Criteria:
- age 19 or older, no medical contraindications, no major psychiatric problems
Locations and Contacts
Karen Cropsey, Psy.D., Phone: 205-917-3786, Ext: 205, Email: kcrospey@beapsy1.his.uab.edu
Pearson Hall, Birmingham, Alabama 35209, United States; Recruiting
Galen, Phone: 205-917-3786, Ext: 207, Email: gjones2@uab.edu
Additional Information
Starting date: June 2006
Ending date: September 2010
Last updated: September 29, 2008
|
